CyberKnife(TM) for the Treatment of Non-Metastatic Prostate Cancer.
10.4111/kju.2009.50.8.744
- Author:
Seung Joon LEE
1
;
Kanghyon SONG
;
Jong Wook PARK
;
Myung Cheol GIL
;
Moon Ki JO
Author Information
1. Department of Urology, Korea Cancer Center Hospital, Seoul, Korea. andrea@kcch.re.kr
- Publication Type:Original Article
- Keywords:
Prostatic neoplasms;
Radiation;
Radiosurgery
- MeSH:
Follow-Up Studies;
Humans;
Prostate;
Prostatic Neoplasms;
Radiobiology;
Radiosurgery;
Survival Rate;
Urinary Bladder
- From:Korean Journal of Urology
2009;50(8):744-750
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The radiobiology of prostate cancer favors a hypofractionated dose regimen. We report here our experience with the CyberKnife(TM), demonstrating its efficacy, safety, and feasibility as a treatment modality for non-metastatic prostate cancer. MATERIALS AND METHODS: Between October 2002 and April 2006, 20 patients with biopsy-proven prostate cancer were treated with the CyberKnife(TM). The distribution of clinical risks, as assessed by using D'Amico's definition for risk grouping, was as follows: low (4), intermediate (5), and high (11). Three patients received 32 Gy, 7 patients received 34 Gy, and 10 patients received 36 Gy. All patients received the radiation doses in 4 fractions. The rectal and bladder toxicities were graded by using the criteria set forth by the Radiation Therapy Oncology Group (RTOG). RESULTS: The mean patient age was 71.4 years (range, 52-79 years), and the mean follow-up period was 35.5 months (range, 8-74 months). There were 2 acute and 1 late grade 2 gastrointestinal toxicities, and 1 acute and 2 late grade 2 urinary toxicities. The 5-year overall survival rate was 100%, respectively. The 5-year biochemical failure-free rate of the low-risk, intermediate-risk, and high-risk patients was 100%, 100%, and 90.9%, respectively. CONCLUSIONS: CyberKnife(TM) is a safe, well-tolerated, and rather effective treatment for non-metastatic prostate cancer. We obtained a 100% 5-year biochemical failure-free rate in low-risk and intermediate-risk patients. CyberKnife(TM) is a viable option for the treatment of non-metastatic prostate cancer.
